(Q34095826)

31 July 2017

1 reference

title

Quality of life in patients with allergic rhinitis (English)

1 reference

31 July 2017

0 references

1 reference

Thompson AK

1

1 reference

31 July 2017

Juniper E

series ordinal

2

1 reference

31 July 2017

Meltzer EO

series ordinal

3

1 reference

31 July 2017

publication date

1 November 2000

1 reference

Annals of Allergy, Asthma & Immunology

31 July 2017

published in

1 reference

31 July 2017

volume

85

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

338-47; quiz 347-8

1 reference

Rhinitis management: the patient's perspective.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Impact of upper respiratory allergic diseases on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

A pharmacologic continuum in the treatment of rhinorrhea: the clinician as economist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Quality of life in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Impact on quality of life during an allergen challenge research trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Measuring health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Measuring quality of life in children with rhinoconjunctivitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Learning impairment and allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Quality of life questionnaires: does statistically significant = clinically important?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Interpretation of quality of life changes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Measurement of health status. Ascertaining the minimal clinically important difference

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

The number needed to treat: a clinically useful nomogram in its proper context

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962543-4

7 January 2021

10.1016/S1081-1206(10)62543-4

Identifiers

DOI

1 reference

31 July 2017

1 reference